Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea

Yang, Rongli; Liu, Chang; Liu, Wenli; Luo, Jintian; Cheng, Shaoli; Mu, Xin

doi:10.1007/s13555-022-00784-0

Cited by 12 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the 207 articles identified in the literature search, 139 were excluded based on the exclusion criteria, leaving 68 publications 20–87 for the further analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Another generic HRQoL instrument EuroQoL (EQ)‐5D 55,67 and its modifications EQ‐5D‐3L 76 and EQ‐5D‐visual analogue scale 77 were also used to assess quimp in rosacea. The dermatology‐specific Dermatology Life Quality Index (DLQI) was used for quimp assessment in 45 studies on rosacea 20–23,25,28–30,32,34,35,37,40–42,46,48–57,60,62–69,72–74,77,78,80,82,83,86,87 . Data on the DLQI scores from included articles is given in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…In several open‐label studies a significant improvement of QoL was reported after use of pulsed dye laser alone 62,65,78,79 and in combination with 1.064 nm neodymium‐doped yttrium aluminium garnet laser 22 and non‐ablative fractional 1440‐nm laser therapy 51 . Intradermal botulinum toxin A injections improved quimp in patients with erythema telangiectasia rosacea with and without non‐laser thermomechanical system 20,54 . After 12 weeks of open‐label metronidazole topical gel 0.75% treatment all DLQI items except “work or study” and “problems with skin treatment” significantly improved 28 .…”

Section: Resultsmentioning

confidence: 99%

“…51 Intradermal botulinum toxin A injections improved quimp in patients with erythema telangiectasia rosacea with and without non-laser thermomechanical system. 20,54 After 12 weeks of open-label metronidazole topical gel 0.75% treatment all DLQI items except "work or study" and "problems with skin treatment" significantly improved. 28 Use of a skin care cream showed improvement of RosaQoL scores on day 29 in subjects with mild-to-moderate erythemato-telangiectatic rosacea.…”

Section: Hrqol Assessment In Clinical Trialsmentioning

confidence: 96%

“…Before (Italia) 87 Lockdown mask users. After (Italia) 87 Before treatment (Israel) 54 Online survey (International) 39 Survey (Germany) 63 Survey (Germany) 52 Before treatment (Germany) 50 Online survey (Germany) 49 Treatment group (Germany) 21 Placebo group (Germany) 21 Online survey (Denmark) 35 Outpatients (China) 74 Before treatment in study group (China) 69 Before treatment in control group (China) 69 Outpatients (China) 68 Rosacea patients with anxiety (China) 66 Rosacea patients with depression (China) 66 Rosacea patients without anxiety (China) 66 Rosacea patients without depression (China) 66 Online survey (China) 60 Outpatients and online survey (China) 53 Before treatment (China) 51 Before treatment (China) 20 Median DLQI…”

Section: R E Su Ltsmentioning

confidence: 99%

See 4 more Smart Citations

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Chernyshov

Finlay

Aragonés

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non‐dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient‐Oriented Outcomes and ARHS recommend the use of the dermatology‐specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea‐specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.

show abstract

“…From the 207 articles identified in the literature search, 139 were excluded based on the exclusion criteria, leaving 68 publications 20–87 for the further analysis.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Hrqol Assessment In Clinical Trialsmentioning

confidence: 96%

Section: R E Su Ltsmentioning

confidence: 99%

See 3 more Smart Citations

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Chernyshov

Finlay

Aragonés

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Efficacy of Botulinum Toxin in the Treatment of Cutaneous Flushing: A Systematic Review and Meta-Analysis

Vincent,

Ravipati,

Reynolds

et al. 2024

Dermatol Surg

View full text Add to dashboard Cite

BACKGROUND Flushing is a common dermatologic complaint and can be resistant to many treatments. As the utility of botulinum toxin continues to expand, recent data suggest that it may also be a therapeutic option for flushing. OBJECTIVE To evaluate the efficacy of botulinum toxin for the treatment of cutaneous flushing. MATERIALS AND METHODS A systematic search of Medline, Embase, Cochrane CENTRAL, CINAHL, Scopus, and Web of Science databases was conducted to identify studies evaluating the effect of botulinum toxin on flushing 1 month after treatment. Prespecified outcome measures included a clinical flushing score, dermatology life quality index (DLQI), and erythema index (EI). Meta-analysis was performed to calculate the mean differences in these outcomes before and after treatment at 1-month follow-up. RESULTS Nine studies (132 patients) were included in the analysis of this study (2 randomized controlled trials and 7 nonrandomized studies). All studies had a low risk of bias (high quality). The most frequent outcome reported was a clinical flushing score, which significantly decreased by 1.25 points overall (95% confidence interval [CI]: −2.47; −0.04) 1 month after treatment with botulinum toxin. Mean DLQI scores decreased (i.e., improved) by 9.02 points (95% CI: −19.81; 1.77) 1 month after botulinum toxin injections. The EI (measured by Mexameter) before and after botulinum toxin was evaluated in 2 studies; however, not enough statistical information was provided to analyze with meta-analytic techniques. CONCLUSION Based on this meta-analysis, botulinum toxin significantly improves clinical flushing scores 1 month after treatment.

show abstract

Long‐term maintenance treatment of rosacea: experts' opinion

Almeida,

Ianhez,

Dal'Forno

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundRosacea is a chronic inflammatory dermatosis characterized by remissions and flares. Although the rosacea active treatment phase is well established, the long‐term maintenance phase is still challenging.ObjectiveTo discuss and make recommendations on how to treat patients during the long‐term maintenance phase for the main rosacea phenotypes.MethodsA panel of six board‐certified Brazilian dermatologists and one American dermatologist gathered to compose a consensus based upon an initial statement on how to treat rosacea during the long‐term maintenance phase based on the methodology Nominal Group Technique. The experts discussed each factor based upon an initial statement on how to treat rosacea patients in the long‐term maintenance phase. A sequence of comprehensive narrative reviews was performed; a questionnaire preparation about the definition of the maintenance phase and its management was presented; an interpersonal discussion and ranking of the ideas were conducted. Recommendations were made if the specialists had 75% agreement.ResultsThe maintenance treatment phase, which starts by achieving IGA 0 or 1 grades at the active phase, should be considered at least during the 9‐month period after remission. The recommendations of all treatments target this period. Daily skincare regimen and sunscreen are crucial. Active treatment phase should be recommended if signs or symptoms reappear or worsen.ConclusionMaintenance phase success depends on patient's adherence to daily skin care, appropriate treatments, continued follow‐up with dermatologist, and self‐assessment to identify new signs and symptoms indicating disease relapse.

show abstract

Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea

Cited by 12 publications

References 21 publications

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Efficacy of Botulinum Toxin in the Treatment of Cutaneous Flushing: A Systematic Review and Meta-Analysis

Long‐term maintenance treatment of rosacea: experts' opinion

Contact Info

Product

Resources

About